Lakshmi Nair, MD
Cardiovascular Disease (Cardiology) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nair’s office at (408) 871-3400 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A109325 · Current
Licensed to practise in California · since 2009 · expires 2027-03-31 · Bangalore University Kempegowda Institute of Medical Science.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$71,287
Medicare paid this office $71,287 for 680 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 401 | $33,352 | $58 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 240 | $9,858 | $41 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 89 | $4,373 | $49 |
| New patient visit (45+ min) | 57 | $4,136 | $73 |
| New patient visit (45+ min) | 26 | $4,132 | $159 |
See all 16 services
| Return visit (30+ min) | 401 | $33,352 | $58 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 240 | $9,858 | $41 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 89 | $4,373 | $49 |
| New patient visit (45+ min) | 57 | $4,136 | $73 |
| New patient visit (45+ min) | 26 | $4,132 | $159 |
| Return visit (30+ min) | 25 | $3,193 | $118 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 13 | $2,522 | $194 |
| New patient visit (30+ min) | 20 | $2,003 | $100 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 135 | $880 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 48 | $717 | $14 |
| Short return visit (20+ min) | 13 | $412 | $32 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 14 | $390 | $19 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 18 | $316 | $17 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 13 | $296 | $23 |
| Heart muscle strain imaging | 40 | $292 | $7 |
| Heart rhythm recording of continous external ekg over 8-15 days | 13 | $165 | $13 |
Who their Medicare patients are
680 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 15% · Women 54% · Also on Medicaid 28% · Health risk score 1.46. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Atrial fibrillation 36% · Diabetes 32% · Coronary heart disease 32% · Heart failure 32% · Chronic kidney disease 28% · COPD 18% · Depression 17% · Cancer 13% · Stroke 10% · Dementia 7%.
The office billed $269,380, Medicare allowed $110,880 and paid $71,287; for 1,433 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 680 | 1,433 | 76 | 1.46 | $269,380 | $71,287 |
| 2023 | 867 | 2,318 | 75 | 1.49 | $360,809 | $134,633 |
| 2022 | 689 | 1,881 | 74 | 1.36 | $385,681 | $120,173 |
| 2021 | 453 | 1,840 | 74 | 1.33 | $336,946 | $107,400 |
| 2020 | 209 | 735 | 73 | 2.48 | $165,534 | $59,717 |
| 2019 | 339 | 1,291 | 76 | 2.51 | $272,865 | $105,952 |
| 2018 | 302 | 1,058 | 75 | 2.92 | $229,293 | $83,739 |
| 2017 | 296 | 968 | 76 | 2.48 | $210,769 | $81,367 |
| 2016 | 456 | 1,672 | 77 | 1.99 | $396,207 | $94,149 |
| 2015 | 490 | 2,868 | 77 | 1.92 | $469,791 | $104,193 |
| 2014 | 557 | 6,601 | 78 | 1.73 | $624,007 | $140,671 |
| 2013 | 634 | 2,287 | 78 | 1.93 | $511,023 | $131,051 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 486 | $82,974 | $72 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 387 | $20,691 | $51 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 193 | $11,242 | $58 |
| New patient visit (45+ min) | 114 | $10,615 | $93 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 96 | $2,133 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 159 | $1,176 | $6 |
| Programming of dual lead pacemaker system | 16 | $572 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 15 | $461 | $20 |
| Heart muscle strain imaging | 12 | $111 | $9 |
2022: 7 services
| Return visit (30+ min) | 439 | $71,721 | $71 |
| New patient visit (45+ min) | 189 | $18,258 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 244 | $13,950 | $54 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 123 | $7,191 | $58 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 84 | $1,903 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 85 | $546 | $6 |
| Programming of dual lead pacemaker system | 12 | $471 | $28 |
2021: 14 services
| Return visit (30+ min) | 323 | $55,200 | $79 |
| New patient visit (45+ min) | 145 | $14,273 | $98 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 176 | $10,247 | $57 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 111 | $7,031 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $6,027 | $163 |
| Short return visit (20+ min) | 41 | $2,862 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,338 | $58 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 84 | $1,913 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 218 | $1,620 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 80 | $1,411 | $18 |
| New patient visit (30+ min) | 21 | $959 | $46 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 80 | $951 | $12 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 13 | $475 | $25 |
| Programming of dual lead pacemaker system | 11 | $412 | $29 |
2020: 7 services
| Return visit (30+ min) | 71 | $20,245 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 91 | $15,297 | $65 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 43 | $8,458 | $197 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $5,112 | $176 |
| New patient visit (45+ min) | 31 | $2,806 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 43 | $2,752 | $63 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 64 | $1,129 | $15 |
2019: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 214 | $39,375 | $64 |
| Return visit (30+ min) | 75 | $19,714 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 99 | $19,229 | $178 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 46 | $9,566 | $204 |
| New patient visit (45+ min) | 44 | $5,735 | $130 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 81 | $5,414 | $66 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 11 | $2,551 | $232 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 77 | $1,494 | $16 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $781 | $71 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 27 | $334 | $12 |
2018: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 197 | $31,506 | $62 |
| Return visit (30+ min) | 57 | $14,357 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $14,084 | $174 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 45 | $9,002 | $200 |
| New patient visit (45+ min) | 35 | $3,672 | $105 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 48 | $3,151 | $64 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 12 | $2,720 | $227 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 16 | $1,034 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 52 | $991 | $15 |
| Analysis and report of external ekg recording for more than 48 hours up to 21 days | 16 | $656 | $39 |
| External ekg recording for more than 48 hours up to 21 days | 16 | $458 | $27 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 19 | $253 | $13 |
2017: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 202 | $34,092 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 82 | $14,690 | $175 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 43 | $9,520 | $221 |
| Return visit (30+ min) | 43 | $8,745 | $96 |
| New patient visit (45+ min) | 47 | $5,439 | $116 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 51 | $3,419 | $67 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 52 | $875 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 11 | $212 | $19 |
2016: 15 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 177 | $33,559 | $189 |
| Return visit (30+ min) | 122 | $15,858 | $77 |
| Short return visit (20+ min) | 171 | $14,232 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $3,906 | $62 |
| Programming of dual lead pacemaker system | 67 | $2,990 | $25 |
| New patient visit (45+ min) | 22 | $2,905 | $132 |
| Short return visit | 24 | $1,972 | $33 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,893 | $172 |
| Programming of dual lead implantable defibrillator system | 15 | $1,864 | $42 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 120 | $1,691 | $13 |
| New patient visit (30+ min) | 20 | $1,410 | $71 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 22 | $1,236 | $56 |
| Programming of multiple lead implantable defibrillator system | 11 | $1,031 | $43 |
| Blood test, clotting time | 31 | $656 | $5 |
| Programming of single lead pacemaker system | 11 | $386 | $24 |
2015: 16 services
| Return visit (30+ min) | 148 | $23,548 | $85 |
| Short return visit (20+ min) | 212 | $22,113 | $54 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $19,546 | $192 |
| Programming of dual lead pacemaker system | 79 | $4,768 | $28 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 67 | $3,731 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $3,630 | $151 |
| Injection, regadenoson, 0.1 mg | 20 | $3,225 | None |
| New patient visit (30+ min) | 35 | $2,750 | $79 |
| Programming of dual lead implantable defibrillator system | 20 | $2,025 | $43 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 105 | $1,804 | $14 |
| Short return visit | 29 | $1,776 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,118 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,073 | $83 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 21 | $801 | None |
| Blood test, clotting time | 27 | $665 | $5 |
| Programming of single lead pacemaker system | 13 | $661 | $24 |
2014: 22 services
| Return visit (30+ min) | 216 | $30,920 | $79 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 99 | $25,443 | $132 |
| Short return visit (20+ min) | 231 | $20,111 | $56 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 68 | $9,872 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,538 | $163 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 117 | $6,481 | $54 |
| Critical care, first 30-74 minutes | 13 | $5,373 | $179 |
| Programming of dual lead pacemaker system | 84 | $4,877 | $29 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $4,710 | $58 |
| Injection, regadenoson, 0.1 mg | 27 | $4,486 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 18 | $3,401 | $189 |
| New patient visit (30+ min) | 38 | $2,921 | $77 |
| Short return visit | 26 | $2,149 | $35 |
| Programming of dual lead implantable defibrillator system | 23 | $2,094 | $42 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 140 | $2,092 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 27 | $1,427 | $49 |
| Programming of multiple lead implantable defibrillator system | 11 | $1,411 | $52 |
| Programming of single lead pacemaker system | 25 | $1,196 | $26 |
| Blood test, clotting time | 37 | $1,105 | $5 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,006 | $84 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 15 | $314 | $20 |
| Evaluation of implantable heart and blood vessel monitoring system | 12 | $226 | $16 |
2013: 18 services
| Return visit (30+ min) | 226 | $37,272 | $80 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 159 | $23,540 | $145 |
| Short return visit (20+ min) | 210 | $18,383 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $9,545 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 72 | $6,057 | $56 |
| New patient visit (30+ min) | 76 | $5,980 | $79 |
| Critical care, first 30-74 minutes | 17 | $5,255 | $170 |
| Programming of dual lead pacemaker system | 82 | $5,192 | $28 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 176 | $2,909 | $14 |
| Programming of dual lead implantable defibrillator system | 25 | $2,199 | $40 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 22 | $1,598 | $69 |
| Blood test, clotting time | 50 | $1,542 | $5 |
| Short return visit | 38 | $1,461 | $29 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 28 | $1,456 | $50 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 24 | $1,384 | $58 |
| Programming of multiple lead implantable defibrillator system | 17 | $1,316 | $42 |
| Programming of single lead pacemaker system | 26 | $1,127 | $25 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $196 | $14 |
Medicaid work
$15,823 in 2024
Medicaid paid $15,823 for 417 billed services this clinician did in 2024, up to 60 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 214 | $7,075 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 113 | $6,259 |
| New patient visit (45+ min) | 16 | $1,623 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 74 | $866 |
| 2024 | 417 | 4 | 60 | $15,823 |
| 2023 | 873 | 5 | 58 | $31,427 |
| 2022 | 662 | 4 | 47 | $27,232 |
| 2021 | 566 | 7 | 49 | $20,538 |
| 2020 | 1,185 | 6 | 63 | $9,334 |
| 2019 | 1,473 | 5 | 52 | $17,617 |
| 2018 | 958 | 6 | 46 | $8,496 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 219 | $14,112 |
| Return visit (30+ min) | 462 | $12,869 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 80 | $2,312 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 98 | $1,429 |
| New patient visit (45+ min) | 14 | $705 |
2022
| Return visit (30+ min) | 463 | $13,341 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 96 | $9,760 |
| New patient visit (45+ min) | 53 | $2,862 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 50 | $1,268 |
2021
| Return visit (30+ min) | 352 | $9,269 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 60 | $5,955 |
| New patient visit (45+ min) | 41 | $2,823 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 35 | $923 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 12 | $845 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 53 | $501 |
| Short return visit (20+ min) | 13 | $222 |
2020
| Return visit (30+ min) | 609 | $4,397 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 181 | $2,581 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 32 | $1,234 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 82 | $792 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 266 | $331 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional | 15 | $0 |
2019
| Return visit (30+ min) | 582 | $6,379 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 115 | $4,452 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 231 | $3,448 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 158 | $2,358 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 387 | $980 |
2018
| Return visit (30+ min) | 438 | $3,057 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 135 | $2,318 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 26 | $1,379 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 91 | $1,296 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 250 | $372 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional | 18 | $74 |
Drugs they prescribed that Part D paid
$411,677
Pharmacies billed $411,677 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,527) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
2,095 generic and 432 brand-name prescriptions · $411,677 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 152 | $180,411 | $1,187 |
| Entresto | 86 | $105,875 | $1,231 |
| Xarelto | 36 | $48,991 | $1,361 |
| Repatha Sureclick | 28 | $24,061 | $859 |
| Repatha | 11 | $5,838 | $531 |
See all 33 drugs
| Eliquis | 152 | $180,411 | $1,187 |
| Entresto | 86 | $105,875 | $1,231 |
| Xarelto | 36 | $48,991 | $1,361 |
| Repatha Sureclick | 28 | $24,061 | $859 |
| Repatha | 11 | $5,838 | $531 |
| Metoprolol | 359 | $4,605 | $13 |
| Diltiazem 24hr Er (Cd) | 72 | $3,332 | $46 |
| Atorvastatin | 299 | $3,069 | $10 |
| Amiodarone | 41 | $1,527 | $37 |
| Furosemide | 269 | $1,501 | $6 |
| Clopidogrel | 70 | $1,196 | $17 |
| Carvedilol | 119 | $1,180 | $10 |
| Rosuvastatin | 55 | $1,053 | $19 |
| Losartan | 84 | $871 | $10 |
| Potassium Chloride | 54 | $842 | $16 |
| Amlodipine Besylate | 150 | $686 | $5 |
| Irbesartan | 23 | $650 | $28 |
| Valsartan | 26 | $567 | $22 |
| Ezetimibe | 32 | $534 | $17 |
| Lovastatin | 17 | $528 | $31 |
| Lisinopril | 66 | $514 | $8 |
| Isosorbide Mononitrate Er | 33 | $503 | $15 |
| Digoxin | 16 | $416 | $26 |
| Nitroglycerin | 32 | $397 | $12 |
| Metoprolol | 59 | $321 | $5 |
| Cartia Xt | 14 | $315 | $22 |
| Clonidine | 25 | $266 | $11 |
| Bumetanide | 12 | $239 | $20 |
| Warfarin | 15 | $235 | $16 |
| Spironolactone | 41 | $221 | $5 |
| Simvastatin | 16 | $188 | $12 |
| Benazepril | 26 | $169 | $6 |
| Hydrochlorothiazide | 28 | $68 | $2 |
Year by year
| 2024 | 2,527 | 460 | 0% (0) | 17% | $411,677 |
| 2023 | 2,941 | 444 | 0% (0) | 16% | $489,077 |
| 2022 | 2,385 | 340 | 0% (0) | 17% | $354,459 |
| 2021 | 1,231 | 263 | 0% (0) | 16% | $147,939 |
| 2020 | 274 | 38 | 0% (0) | 23% | $34,989 |
| 2019 | 238 | 51 | 0% (0) | 28% | $35,489 |
| 2018 | 220 | 33 | 0% (0) | 20% | $12,448 |
| 2017 | 298 | 81 | None | 22% | $16,057 |
| 2016 | 1,088 | 170 | None | 27% | $66,551 |
| 2015 | 1,126 | 190 | 0% (0) | 22% | $59,174 |
| 2014 | 958 | 203 | 0% (0) | None | $33,206 |
| 2013 | 1,012 | 247 | 0% (0) | 21% | $31,166 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 37 drugs
| Eliquis | 208 | $233,500 | $1,123 |
| Entresto | 85 | $107,923 | $1,270 |
| Xarelto | 52 | $71,679 | $1,378 |
| Repatha Sureclick | 13 | $8,008 | $616 |
| Metoprolol | 351 | $6,746 | $19 |
| Atorvastatin | 275 | $4,729 | $17 |
| Diltiazem 24hr Er (Cd) | 69 | $3,101 | $45 |
| Amiodarone | 110 | $3,011 | $27 |
| Propafenone | 17 | $2,782 | $164 |
| Furosemide | 303 | $2,522 | $8 |
| Carvedilol | 165 | $1,916 | $12 |
| Irbesartan | 28 | $1,897 | $68 |
| Clopidogrel | 86 | $1,849 | $21 |
| Potassium Chloride | 55 | $1,834 | $33 |
| Amlodipine Besylate | 191 | $1,702 | $9 |
| Losartan | 100 | $1,545 | $15 |
| Fenofibrate | 18 | $1,373 | $76 |
| Rosuvastatin | 51 | $1,333 | $26 |
| Isosorbide Mononitrate Er | 44 | $1,318 | $30 |
| Valsartan | 55 | $1,262 | $23 |
| Ezetimibe | 31 | $1,061 | $34 |
| Digoxin | 18 | $786 | $44 |
| Lisinopril | 102 | $782 | $8 |
| Cartia Xt | 21 | $760 | $36 |
| Metoprolol | 63 | $746 | $12 |
| Spironolactone | 67 | $698 | $10 |
| Nifedipine Er | 19 | $664 | $35 |
| Nebivolol | 11 | $601 | $55 |
| Nitroglycerin | 33 | $450 | $14 |
| Hydralazine | 21 | $370 | $18 |
| Clonidine | 21 | $354 | $17 |
| Simvastatin | 28 | $323 | $12 |
| Olmesartan Medoxomil | 11 | $249 | $23 |
| Benazepril | 24 | $238 | $10 |
| Warfarin | 18 | $221 | $12 |
| Atenolol | 12 | $191 | $16 |
| Hydrochlorothiazide | 23 | $79 | $3 |
2022: 33 drugs
| Eliquis | 173 | $190,282 | $1,100 |
| Entresto | 48 | $61,518 | $1,282 |
| Xarelto | 39 | $45,724 | $1,172 |
| Metoprolol | 284 | $5,410 | $19 |
| Diltiazem 12hr Er | 12 | $3,662 | $305 |
| Diltiazem 24hr Er (Cd) | 75 | $3,123 | $42 |
| Atorvastatin | 242 | $3,064 | $13 |
| Furosemide | 236 | $2,223 | $9 |
| Potassium Chloride | 77 | $2,191 | $28 |
| Carvedilol | 145 | $2,004 | $14 |
| Amiodarone | 64 | $1,447 | $23 |
| Irbesartan | 37 | $1,425 | $39 |
| Bumetanide | 19 | $1,425 | $75 |
| Propafenone | 21 | $1,378 | $66 |
| Clopidogrel | 74 | $1,342 | $18 |
| Digoxin | 14 | $1,216 | $87 |
| Amlodipine Besylate | 122 | $1,000 | $8 |
| Isosorbide Mononitrate Er | 45 | $993 | $22 |
| Losartan | 75 | $887 | $12 |
| Ezetimibe | 17 | $739 | $43 |
| Spironolactone | 73 | $658 | $9 |
| Lisinopril | 98 | $623 | $6 |
| Rosuvastatin | 32 | $488 | $15 |
| Metoprolol | 57 | $424 | $7 |
| Nitroglycerin | 24 | $396 | $16 |
| Atenolol | 11 | $344 | $31 |
| Warfarin | 23 | $271 | $12 |
| Hydralazine | 13 | $221 | $17 |
| Lovastatin | 12 | $205 | $17 |
| Clonidine | 13 | $182 | $14 |
| Simvastatin | 18 | $180 | $10 |
| Benazepril | 12 | $171 | $14 |
| Hydrochlorothiazide | 24 | $92 | $4 |
2021: 24 drugs
| Eliquis | 75 | $70,585 | $941 |
| Xarelto | 23 | $27,247 | $1,185 |
| Entresto | 11 | $14,548 | $1,323 |
| Metoprolol | 139 | $2,623 | $19 |
| Potassium Chloride | 58 | $1,662 | $29 |
| Atorvastatin | 108 | $1,378 | $13 |
| Diltiazem 24hr Er (Cd) | 27 | $1,234 | $46 |
| Furosemide | 103 | $871 | $8 |
| Propafenone | 12 | $770 | $64 |
| Amiodarone | 14 | $750 | $54 |
| Carvedilol | 65 | $737 | $11 |
| Irbesartan | 30 | $719 | $24 |
| Nitroglycerin | 42 | $649 | $15 |
| Lisinopril | 61 | $561 | $9 |
| Isosorbide Mononitrate Er | 38 | $554 | $15 |
| Losartan | 43 | $549 | $13 |
| Clopidogrel | 25 | $417 | $17 |
| Amlodipine Besylate | 66 | $414 | $6 |
| Metoprolol | 47 | $394 | $8 |
| Spironolactone | 19 | $249 | $13 |
| Hydralazine | 13 | $220 | $17 |
| Rosuvastatin | 19 | $176 | $9 |
| Simvastatin | 14 | $172 | $12 |
| Warfarin | 13 | $89 | $7 |
2020: 8 drugs
| Eliquis | 25 | $22,928 | $917 |
| Metoprolol | 21 | $464 | $22 |
| Carvedilol | 45 | $449 | $10 |
| Potassium Chloride | 21 | $366 | $17 |
| Furosemide | 58 | $254 | $4 |
| Atorvastatin | 22 | $219 | $10 |
| Isosorbide Mononitrate Er | 14 | $109 | $8 |
| Spironolactone | 13 | $99 | $8 |
2019: 7 drugs
| Eliquis | 23 | $16,519 | $718 |
| Carvedilol | 27 | $441 | $16 |
| Nitroglycerin | 20 | $400 | $20 |
| Metoprolol | 19 | $321 | $17 |
| Isosorbide Mononitrate Er | 12 | $176 | $15 |
| Amlodipine Besylate | 13 | $125 | $10 |
| Furosemide | 29 | $73 | $3 |
2018: 6 drugs
| Eliquis | 16 | $6,280 | $393 |
| Valsartan | 16 | $339 | $21 |
| Carvedilol | 34 | $324 | $10 |
| Hydralazine | 20 | $311 | $16 |
| Furosemide | 29 | $88 | $3 |
| Losartan | 13 | $47 | $4 |
2017: 11 drugs
| Eliquis | 11 | $4,234 | $385 |
| Olmesartan Medoxomil | 16 | $2,489 | $156 |
| Atorvastatin | 17 | $655 | $39 |
| Metoprolol | 25 | $497 | $20 |
| Carvedilol | 27 | $237 | $9 |
| Amlodipine Besylate | 12 | $133 | $11 |
| Lisinopril | 24 | $121 | $5 |
| Isosorbide Mononitrate Er | 14 | $119 | $9 |
| Metoprolol | 13 | $110 | $8 |
| Furosemide | 22 | $105 | $5 |
| Clonidine | 12 | $40 | $3 |
2016: 29 drugs
| Xarelto | 18 | $11,549 | $642 |
| Pradaxa | 17 | $9,306 | $547 |
| Eliquis | 16 | $7,605 | $475 |
| Benicar | 21 | $7,086 | $337 |
| Nitrostat | 41 | $2,358 | $58 |
| Metoprolol | 90 | $2,114 | $23 |
| Valsartan | 30 | $1,262 | $42 |
| Carvedilol | 113 | $1,210 | $11 |
| Atorvastatin | 51 | $1,139 | $22 |
| Digoxin | 20 | $1,105 | $55 |
| Valsartan-Hydrochlorothiazide | 17 | $539 | $32 |
| Amiodarone | 27 | $500 | $19 |
| Isosorbide Mononitrate Er | 50 | $499 | $10 |
| Clopidogrel | 26 | $474 | $18 |
| Lisinopril | 59 | $465 | $8 |
| Potassium Chloride | 20 | $465 | $23 |
| Warfarin | 24 | $459 | $19 |
| Furosemide | 92 | $396 | $4 |
| Diltiazem 24hr Er | 12 | $391 | $33 |
| Amlodipine Besylate | 49 | $317 | $6 |
| Hydralazine | 17 | $260 | $15 |
| Ramipril | 12 | $233 | $19 |
| Metoprolol | 18 | $182 | $10 |
| Simvastatin | 17 | $177 | $10 |
| Sotalol | 11 | $175 | $16 |
| Losartan | 13 | $163 | $13 |
| Spironolactone | 20 | $156 | $8 |
| Hydrochlorothiazide | 19 | $81 | $4 |
| Clonidine | 12 | $44 | $4 |
2015: 28 drugs
| Xarelto | 15 | $8,483 | $566 |
| Eliquis | 19 | $6,611 | $348 |
| Benicar | 22 | $6,055 | $275 |
| Ranexa | 16 | $4,520 | $282 |
| Valsartan | 27 | $3,537 | $131 |
| Metoprolol | 87 | $2,210 | $25 |
| Nitrostat | 45 | $1,569 | $35 |
| Carvedilol | 136 | $1,112 | $8 |
| Atorvastatin | 57 | $1,080 | $19 |
| Cartia Xt | 22 | $839 | $38 |
| Potassium Chloride | 26 | $819 | $32 |
| Clopidogrel | 47 | $750 | $16 |
| Isosorbide Mononitrate Er | 51 | $652 | $13 |
| Enalapril Maleate | 12 | $569 | $47 |
| Diltiazem 24hr Er | 19 | $564 | $30 |
| Amiodarone | 21 | $475 | $23 |
| Nitroglycerin Patch | 15 | $392 | $26 |
| Warfarin | 21 | $376 | $18 |
| Hydralazine | 11 | $309 | $28 |
| Furosemide | 78 | $308 | $4 |
| Amlodipine Besylate | 51 | $266 | $5 |
| Simvastatin | 27 | $265 | $10 |
| Lisinopril | 42 | $207 | $5 |
| Levothyroxine | 13 | $203 | $16 |
| Spironolactone | 29 | $200 | $7 |
| Metoprolol | 31 | $193 | $6 |
| Hydrochlorothiazide | 20 | $99 | $5 |
| Losartan | 15 | $85 | $6 |
2014: 23 drugs
| Diovan | 28 | $3,319 | $119 |
| Ranexa | 13 | $3,052 | $235 |
| Metoprolol | 69 | $1,671 | $24 |
| Nitrostat | 44 | $1,321 | $30 |
| Isosorbide Mononitrate Er | 78 | $1,275 | $16 |
| Carvedilol | 96 | $932 | $10 |
| Digox | 18 | $861 | $48 |
| Digoxin | 13 | $784 | $60 |
| Clopidogrel | 39 | $781 | $20 |
| Nitroglycerin Patch | 27 | $595 | $22 |
| Potassium Chloride | 11 | $565 | $51 |
| Metoprolol | 57 | $412 | $7 |
| Levothyroxine | 12 | $329 | $27 |
| Warfarin | 39 | $299 | $8 |
| Lisinopril | 42 | $295 | $7 |
| Furosemide | 61 | $280 | $5 |
| Atorvastatin | 11 | $255 | $23 |
| Enalapril Maleate | 21 | $222 | $11 |
| Spironolactone | 26 | $198 | $8 |
| Amlodipine Besylate | 24 | $197 | $8 |
| Simvastatin | 19 | $197 | $10 |
| Atenolol | 12 | $113 | $9 |
| Hydrochlorothiazide | 26 | $87 | $3 |
2013: 19 drugs
| Diovan | 32 | $5,475 | $171 |
| Isosorbide Mononitrate Er | 133 | $2,083 | $16 |
| Metoprolol | 58 | $1,833 | $32 |
| Nitrostat | 87 | $1,807 | $21 |
| Clopidogrel | 23 | $1,596 | $69 |
| Carvedilol | 76 | $1,013 | $13 |
| Warfarin | 44 | $471 | $11 |
| Metoprolol | 86 | $462 | $5 |
| Amiodarone | 12 | $346 | $29 |
| Lisinopril | 48 | $333 | $7 |
| Simvastatin | 32 | $309 | $10 |
| Digox | 16 | $285 | $18 |
| Amlodipine Besylate | 31 | $285 | $9 |
| Furosemide | 68 | $270 | $4 |
| Losartan | 20 | $247 | $12 |
| Spironolactone | 31 | $243 | $8 |
| Potassium Chloride | 16 | $238 | $15 |
| Hydrochlorothiazide | 24 | $97 | $4 |
| Enalapril Maleate | 12 | $85 | $7 |
Money from drug and device companies
$125 in 2024
| 2024 | 3 | 3 | None | $125 |
| 2023 | 5 | 5 | None | $349 |
| 2022 | 7 | 7 | None | $353 |
| 2021 | 2 | 2 | None | $158 |
| 2020 | 1 | 1 | None | $13 |
| 2019 | 1 | 1 | None | $15 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Teva Pharmaceuticals USA | None | $101 | 1 payment
|
| Amgen | Repatha | $17 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $6 | 1 payment
|
See all 3 published payments
| Teva Pharmaceuticals USA | Education · 2024-10-23 | None | $101 |
| Amgen | Meals · 2024-05-23 | Repatha | $17 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2024-02-28 | Lifevest | $6 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $349
| AstraZeneca Pharmaceuticals LP | Fasenra | $125 | 1 payment
|
| Genzyme | Dupixent | $120 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $49 | 1 payment
|
| Amgen | Repatha | $29 | 1 payment
|
| Boston Scientific | Watchman Flx | $26 | 1 payment
|
2022: $353
| Boston Scientific | Watchman Access System | $137 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $120 | 1 payment
|
| Vanda Pharmaceuticals | Hetlioz | $28 | 1 payment
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $26 | 1 payment
|
| Abbott Laboratories | Assurity | $23 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $12 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $6 | 1 payment
|
2021: $158
| Allergan | Natrelle Saline-Filled Breast Implants | $138 | 1 payment
|
| Abbott Laboratories | Cardiomems Hf System | $20 | 1 payment
|
2020: $13
| Actelion Pharmaceuticals US | Opsumit | $13 | 1 payment
|
2019: $15
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $15 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 85.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1891951760
- Licence
- AZ 41779, CA A109325California A109325: Current · expires 2027-03-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- AZ 518434
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 27206 Calaroga Ave, Ste 115, Hayward, CA, 94545
- NPI first listed
- 2008-07-31
- NPI last updated
- 2016-11-29
This is when the NPI record was last certified, not a medical board exam.